619 related articles for article (PubMed ID: 37216792)
21. SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine.
Clémenceau B; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Le Bourgeois A; Jullien M; Ollier J; Grain A; Béné MC; Vié H; Chevallier P
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335079
[TBL] [Abstract][Full Text] [Related]
22. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
Canti L; Humblet-Baron S; Desombere I; Neumann J; Pannus P; Heyndrickx L; Henry A; Servais S; Willems E; Ehx G; Goriely S; Seidel L; Michiels J; Willems B; Liston A; Ariën KK; Beguin Y; Goossens ME; Marchant A; Baron F
J Hematol Oncol; 2021 Oct; 14(1):174. PubMed ID: 34689821
[TBL] [Abstract][Full Text] [Related]
23. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
24. Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients.
Lindemann M; Klisanin V; Thümmler L; Fisenkci N; Tsachakis-Mück N; Ditschkowski M; Schwarzkopf S; Klump H; Reinhardt HC; Horn PA; Koldehoff M
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696183
[TBL] [Abstract][Full Text] [Related]
25. Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination.
Pizzano U; Facchin G; Marcon C; Fabris M; Battista ML; Cerno M; Geromin A; Pucillo M; Petruzzellis G; Vianello G; Battaglia G; Peressutti R; Grillone L; Tascini C; Curcio F; Fanin R; Patriarca F
Transpl Infect Dis; 2023 Apr; 25(2):e14003. PubMed ID: 36748718
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
EClinicalMedicine; 2023 May; 59():101983. PubMed ID: 37128256
[TBL] [Abstract][Full Text] [Related]
28. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
[TBL] [Abstract][Full Text] [Related]
29. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
[TBL] [Abstract][Full Text] [Related]
30. Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients.
Herrera S; Colmenero J; Pascal M; Escobedo M; Castel MA; Sole-González E; Palou E; Egri N; Ruiz P; Mosquera M; Moreno A; Juan M; Vilella A; Soriano A; Farrero M; Bodro M
Am J Transplant; 2021 Dec; 21(12):3971-3979. PubMed ID: 34291552
[TBL] [Abstract][Full Text] [Related]
31. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
Sharifi Aliabadi L; Azari M; Taherian MR; Barkhordar M; Abbas SAM; Azari M; Ahmadvand M; Salehi Z; Rouzbahani S; Vaezi M
Virol J; 2024 May; 21(1):103. PubMed ID: 38702752
[TBL] [Abstract][Full Text] [Related]
32. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
33. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
36. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
37. Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia.
Rocco JM; Boswell KL; Laidlaw E; Epling B; Anderson M; Serebryannyy L; Narpala S; O'Connell S; Kalish H; Kelly S; Porche S; Oguz C; McDermott A; Manion M; Koup RA; Lisco A; Sereti I
J Allergy Clin Immunol; 2024 Feb; 153(2):503-512. PubMed ID: 38344971
[TBL] [Abstract][Full Text] [Related]
38. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
39. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients.
Chiarucci M; Paolasini S; Isidori A; Guiducci B; Loscocco F; Capalbo M; Visani G
Front Oncol; 2021; 11():737300. PubMed ID: 34552880
[TBL] [Abstract][Full Text] [Related]
40. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]